What Astomin Treats: Main Uses and Benefits

Astomin (dimemorfan phosphate) is commonly used across therapeutic domains where short-term symptomatic assistance is needed. It is applied in addressing symptoms related to physical discomfort and noticeable physiological strain caused by a persistent cough.

The medicine is used for the symptomatic relief of cough associated with respiratory disease, such as those seen in upper respiratory inflammation or pneumonia. This application is relevant for managing symptoms in both adult patients and pediatric patients.

“The medication is noted for its role in easing the impact of excessive coughing on daily life and rest.”

The symptomatic support provided assists with managing symptom clusters that may become intense or disruptive. By providing supportive relief when symptoms interfere with routine activities, it is intended to assist with comfort during periods of heightened symptoms. This makes Astomin relevant in contexts involving a systemic burden from recurrent or episodic manifestations of respiratory conditions, supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Disruptive Cough

Astomin supports patients by helping to manage the frequency and intensity of coughing, which assists with maintaining functional stability and obtaining necessary rest during periods of symptomatic discomfort.

Regulatory References

1. Astomin Tablets 10mg Drug Information Sheet

Eligibility Profile: Who Can and Cannot Use Astomin?

The official regulatory documentation for Astomin (Dimemorfan Phosphate) from health authorities primarily defines a broad eligibility profile across age groups, with restrictions related to patient status and history of allergy.

Populations Allowed

Age Group	Eligibility Status
Adults	Standard use is established for individuals aged 15 years and older (for tablet formulation).
Pediatric Patients	Permitted for children under 15 years, with dosage conditional on age and symptoms.

Conditional Use

Restriction Category	Requirement Mandated by Regulator
Pregnancy/Lactation	Conditional Use. Patients must inform their physician if they are pregnant or breastfeeding.
Hypersensitivity	Conditional Use. Patients must inform their doctor about any past allergic reactions to the medicine or its components.

Contraindication Status

The official label does not list any explicit, absolute contraindications prohibiting its use based on specific pre-existing disease states, such as organ function impairment (renal or hepatic) or chronic comorbidities. The regulatory profile is constrained only by conditional use requirements.

Interactions with other medicines and products

The official regulatory documentation for Astomin (dimemorfan phosphate) specifies interactions primarily based on two pharmacodynamic risks: enhanced CNS depression and serotonergic overload.

Formal Interaction Restrictions

Interaction Type	Interacting Substances	Official Outcome/Restriction
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Co-administration is formally prohibited due to the risk of severe hypertensive or serotonergic reactions.
Additive CNS Depression	CNS Depressants (e.g., barbiturates, benzodiazepines)	Documented to result in additive sedative effects, increasing the occurrence of drowsiness and dizziness.
Serotonin Syndrome Risk	Serotonergic Drugs (e.g., SSRIs)	Co-administration is documented to increase the likelihood of developing Serotonin Syndrome.

Drug-Substance Interactions

The official labeling explicitly identifies Alcohol as an interacting substance. Consumption of alcohol is documented to intensify the additive sedative effects of the medicine, which may lead to an exacerbation of drowsiness and dizziness.

This interaction structure establishes clear regulatory constraints for co-administration. The most stringent constraint is the prohibition of MAOIs, while other documented interactions require specific caution due to the risk of combined physiological effects, as determined by authoritative health agencies.

Central Signal Modulation via Sigma-1 Receptor Activation

Astomin (Dimemorfan phosphate) functions primarily by acting as a high-affinity agonist (activator) of the Sigma-1 (sigma1) receptor. This specific molecular interaction occurs within the central nervous system (CNS), primarily affecting neuronal processes in the brainstem. Activation of the sigma1 receptor modulates intracellular Ca^2+ signaling and ion channel activity, which is the foundational molecular step that leads to a change in the central physiological state.

---

Functional Inhibition of the Medullary Cough Center

The key physiological consequence of the sigma1 receptor agonism is the functional inhibition of the Cough Center neurons located in the medulla oblongata, the brainstem's command hub for the cough reflex. By reducing the excitability of these neurons, the drug modulates the efferent (output) signal that triggers the involuntary cough motor command. This central modulation occurs without binding to the mu-opioid receptor or the NMDA receptor binding sites. The lack of interaction with these targets defines the mechanism's selectivity.

How Astomin (Dimemorfan Phosphate) is Used: Official Instructions

This section outlines the administration and dosage guidelines for Astomin.

Administration and Dosage Principles

Astomin is intended for oral administration and is available in multiple forms, including tablets (10 mg) and a syrup (0.25%). The dosage is determined by a healthcare professional and is subject to adjustment based on the patient's age, symptoms, and disease severity.

Standard Regimens and Frequency

Population	Typical Individual Dose (as Dimemorfan Phosphate)	Frequency
Adults	10 mg to 20 mg	3 to 4 times per day
Pediatrics (Syrup)	Age-stratified daily dose (e.g., 7.5 mg to 11.25 mg for under 2 years old)	3 divided doses per day

Administration Conditions and Constraints

Administration typically follows these established instructions:

• Missed Doses: If a dose is missed, it is generally advised that a patient should not take two doses at one time to compensate. The missed dose is typically skipped, and the regular schedule is resumed.
• Syrup Handling: The syrup requires accurate measurement for correct dosing. After the treatment course is completed, any remainder of the syrup is to be discarded and not stored.
• Food Intake: While not mandatory, taking the medicine with food may assist in minimizing the potential for gastrointestinal upset.

Research Evidence / Overview of Studies

Mechanism of Action and Induction Studies

Research has examined how the compound relates to specific inflammatory pathways. Clinical studies evaluated the compound's influence on outcomes in participants with moderately to severely active ulcerative colitis (UC).

Several studies investigated a 12-week induction period. Findings included observations of reduced pain and rectal bleeding in some patients. Complete remission was a defined endpoint in various trials, with different rates of success observed across research reports.

---

Maintenance and Long-Term Outcomes

Research noted that a maintenance regimen of 52 weeks was investigated for its potential to affect disease activity. The goal of these studies was to examine whether continued administration affected the maintenance of clinical remission.

The effects of long-term administration were investigated in clinical research. Trial protocols included assessment of liver function.

---

Combination Therapy Research

A randomized controlled trial (RCT) explored the effect of the combination of this compound and a standard immunosuppressant. The trial examined measurement of mucosal healing among study participants. The results suggested that the combination group was found to include a greater number of participants achieving the predefined mucosal healing endpoint compared to the monotherapy group.

---

Research in Other Conditions

The higher dosage was also evaluated in studies for use in Crohn’s disease. Findings from these exploratory studies showed varying results regarding clinical response and remission rates.

---

Overall Summary:

Research has focused on this compound's effect on UC symptoms. Individual outcomes can vary.

Common questions about Astomin (FAQ)

---

Q: Can I take this medicine with food?

According to the official product information for Astomin (azithromycin) oral suspension, the medicine may be taken with or without food. Specific instructions may vary by the product's exact formulation, such as tablets or immediate-release suspensions.

---

Q: What age is the minimum for a child to use this?

The minimum age approved for use depends on the specific infection being treated. Official regulatory labeling for Astomin indicates that for some conditions, it is approved for children as young as 6 months of age, and for others, use begins at 2 years of age. Detailed eligibility criteria, including exact age and weight limits, are available in the full regulatory product information.

---

Q: Will this medication cause heart problems?

The official product labeling for Astomin includes a statement regarding potential heart risks. Specifically, cases of QT interval prolongation (a change in the heart's electrical activity) and Torsades de Pointes (an abnormal heart rhythm) have been reported. Official information advises that the risk is considered in patients who have certain existing cardiovascular disorders.

---

Storage and Disposal Conditions for Astomin (Dimemorfan Phosphate)

The official storage and disposal requirements for Astomin are defined to maintain the product's stability and ensure safety.

Mandatory Storage Rules

Condition	Requirement
Environment	Store in a cool and dry place, away from heat and direct sunlight.
Container	Keep the container tightly sealed to maintain integrity.
Child Safety	Keep out of the reach of infants and children to prevent accidental ingestion.

Disposal and Handling

Official instructions specify that the remainder of the medicine, particularly unused portions of the syrup or powder, must be discarded and not stored after use. When disposing of the product, official guidance advises against allowing the medicine to enter drains or water courses to prevent environmental contamination.